Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 06, 2022

Impact of TAILORx on Chemotherapy Prescribing and 21-Gene Recurrence Score–Guided Treatment Costs in Patients With Breast Cancer



Additional Info

Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer
Cancer 2022 Feb 15;128(4)665-674, ME Tesch, C Speers, RM Diocee, L Gondara, SJ Peacock, A Nichol, CA Lohrisch

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading